secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2024-08-30T23:59:59+00:00
Accession:  0000950103-24-012981
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Precigen grants PSUs tied to PRGN-2012 BLA milestones to named execs
--------------------------------------------------------------------

- Target PSUs granted: CEO Helen Sabzevari 1,650,000; CFO Harry Thomasian 250,000; COO Rutul Shah 250,000; CLO Donald Lehr 108,000.
- Vesting in two 50% installments upon: (1) FDA submission of BLA for PRGN-2012, (2) FDA approval of BLA, both by Dec 31, 2026.
- PSUs forfeited if milestones not achieved by end of Performance Period; vesting accelerated upon change in control in certain cases.
- Pro-rata vesting applies on termination without cause or for good reason; full forfeiture on other termination events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324012981/0000950103-24-012981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324012981/dp217405_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-24-012981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer